CNS Disorders  >>  Intuniv (guanfacine XR)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuniv (guanfacine XR) / Shionogi, Takeda
NCT00151996: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
2
75
NA
Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503
Shire
Attention Deficit Disorder With Hyperactivity
12/04
12/04
NCT00150592: Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Completed
2
182
NA
SPD503 (Guanfacine HCl), Placebo
Shire
Attention Deficit Disorder With Hyperactivity
10/05
10/05
NCT01470469: SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Completed
2
83
US
SPD503 (extended-release Guanfacine hydrochloride), Intuniv, Placebo
Shire
Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
07/13
07/13

Download Options